Kolltan Pharmaceuticals (New Haven, CT) an early-stage developer of oncology therapeutics leveraging the receptor tyrosine kinase targets closed a $5M Series A, bring the total financing round to $40M. Participants include Purdue Pharma, HBM Bioventures, the Pritzker family and Diaz and Altschul Capital Management.